Why CUE rose 60.1% on Sep 21 2026: phase 2 data
CUE+60.1%on Mon Sep 21 2026
Cue Biopharma, Inc. was up 60.1% on the day at $59.30, ranked #1 on 75.4× its usual five-minute volume, when TapeRank recorded this spike at 04:06 ET during the pre-market session.
THE DAY ON THE LIST · 1 EVENT
- 04:06 ETMOVER · PRE-MARKET
$59.30 · ▲ 60.1% ON THE DAY · 75.4× 5M RVOL · RANK #1
STRETCHEDCONFIDENCE4/5Cue Biopharma is up 26.9% pre-market after Phase 2 CUE-221 data showed 60% complete hives resolution at 12 weeks off treatment versus 24% for omalizumab. The statistically significant efficacy and favorable safety results are a concrete catalyst, but the reported post hoc comparison and early-stage study do not clearly support a move of this magnitude.
WHYUp 26.9% on Phase 2 efficacy data and a post hoc comparator advantage is a substantial move relative to the still-early, unquantified commercial significance of the news.ANALYZED 04:05 ET · 1 MIN AGO · OPENAI/GPT-5.6-LUNATHE ROW AND SESSION LEVELS AT 04:06 ET
LAST59.30DAY▲ 60.1%5 MIN▲ 30.16%5M RVOL75.4×5M $VOL$523KFLOAT*7.3MRANK#1SESSIONPRE-MARKETVWAP47.78HOD52.00LOD45.56OR HIGH—OR LOW—PREV CLOSE37.05PM HIGH52.00PM LOW45.56GAP▲ 40.35% (indicated)* FLOAT IS SHARES OUTSTANDING; TRUE FREE FLOAT IS NOT AVAILABLE
— MEANS THE LEVEL DID NOT EXIST YET AT THAT INSTANT, NOT ZERO
THE SESSION
- 09:30 ETOpened at $38.50, +3.9% on the previous close of $37.05
- 09:30 ETRegular-session high, $41.50
- 12:51 ETRegular-session low, $23.80
- 15:59 ETLast trade of the regular session, $28.27, -23.7% on the previous close of $37.05
- Volume: 2.5M shares in regular hours, 859K before the open
CUE opened at $38.50 and immediately reached $41.50 after TapeRank tied the move to Phase 2 CUE-221 data showing 60% complete hives resolution 12 weeks off treatment versus 24% for omalizumab in a post hoc analysis. The stock then reversed without any halts, falling to $23.80 at 12:51 ET before recovering to finish at $28.27, below the previous close of $37.05. TapeRank described the catalyst as stretched because the efficacy and safety results were favorable, but the early-stage, post hoc comparison did not clearly support a move of that magnitude.
WRITTEN THU OCT 15 2026 17:52 ET BY OPENAI/GPT-5.6-LUNA FROM THE FACTS ON THIS PAGE
FILINGS AND NEWS · 24H BEFORE THE MOVE
On the tape right now
WHERE THE LIST STOODWED NOV 4 2026 · 13:49 ETRECORDED LIVE · 742 QUALIFY
Open the full list